drugset / Trial / NCT01433406

Long-term Study of TAK-875

NCT01433406

Phase 3 Completed 1222 enrolled Takeda
Parallel-group

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with TAK-875 in diabetic patients.

Timeline

Start
2011-10
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasiglifam Small molecule 25 mg
Subject Fasiglifam Small molecule 50 mg

Indications